![]() It ranks second in each category, which propelled it to the top spot overall. TaylorMade Stealth 2 Plus provided distance and accuracy for our entire testing pool. View More Most Wanted Driver 2023: TaylorMade Stealth 2 Plus Bottom Line Whether you are seeking more distance, accuracy or forgiveness, there is a driver out there for you. Determine your area of weakness and identify the best-performing drivers in that area. From there, categories are then weighted (slightly favoring distance) and aggregated to form the overall rankings.Įvery golfer is different. ScoringĮach individual metric is weighted within each corresponding category. However, at the same time, a club can have a tight grouping and not be the straightest. Picture the ellipse associated with most launch monitor software that surrounds a grouping of shots. Shot Area – In its simplest form, dispersion. Our forgiveness category takes a deeper dive into how forgiveness translates to the golf course.Ĭarry Delta – The difference in yards between the longest and shortest shot hit by each tester with each golf club.īall Speed Delta – The speed difference between the fastest and slowest shots hit by each tester with each golf club. Typically, forgiveness is tied to MOI (moment of inertia) or how much MOI a golf club has. We identify a playable shot as one that is in or within 10 yards of the edge of a 35-yard-wide fairway. Playable Shot Percentage – Obviously, a playable shot is ideal. The target area widens the further a shot is hit. However, shots aren’t penalized for missing the fairway simply because they were a few yards longer. Straight Shot Percentage – Think of this as an adjusted Fairway Percentage. The purpose of our accuracy category is to help you identify the golf clubs that fly straight, helping you avoid penalty strokes. However, we firmly believe accuracy’s importance needs to be emphasized. This leaves RNA therapeutics as a potential breakthrough strategy, and a prime use-case for miRecule and Sanofi.For most golfers, distance is the priority. Since FSHD is caused by a mutation in a transcription factor, it’s particularly challenging to treat with traditional methods such as small molecules and biologics. The progressive disease primarily affects younger patients, and today, it has no approved therapies. Such is the case for Facioscapulohumeral Muscular Dystrophy, or FSHD, an inherited muscle disorder and the second most common type of muscular dystrophy. Uncovering these underlying drivers is critical to rare disease treatment, where drug targets are especially difficult to access. “At miRecule, we've designed our DREAmiR TM platform to understand using patient data, sequencing data, and expression data, how to design that RNA therapeutic and match it up to correct the underlying disorder for patients.” Working to address a debilitating genetic disorder “Many of our diseases are caused by mutations either spontaneously or inherited from our parents that result in defective mRNAs that become disease proteins, which cause the disease itself,” said Saleh. ![]() ![]() This was the foundation for miRecule’s innovative DREAmiR TM discovery platform. To solve this problem, Saleh developed a platform that analyzes genomic and outcome data from thousands of patients to find genetic mutations that cause their disease. But RNA molecules are particularly large, and transporting these therapies into the right cells remains a consistent obstacle in drug development.Īdditionally, a greater understanding of the underlying causes of disease is necessary before researchers can develop an RNA molecule that will target these factors. Quickly, he determined it was an area he wanted to work in for the rest of his career.Įven back in the early 2000s, Saleh saw RNA therapeutics for their potential to treat diseases caused by genetic mutations. It was during his time at the NIH that he was first drawn to therapeutic design and the concept of RNA therapeutics. in biochemistry from Johns Hopkins University and then worked at the National Institutes of Health (NIH), focusing on microRNA and nucleic acid chemistry. Before his career as an inventor and biotech entrepreneur, Saleh earned a Ph.D. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |